A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
about
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropeniaAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsFungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?Hypoxia and fungal pathogenesis: to air or not to air?Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Clinical Translation of Nanomedicine.Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lysPre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patientsTherapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin.Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Aspergillus infections in transplant recipients.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BSystematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Fungal infections in transplant and oncology patients.Nanopharmaceuticals (part 1): products on the market.Canadian clinical practice guidelines for invasive candidiasis in adults.Treatment options in Invasive Aspergillosis.Antifungal agents for the treatment of systemic fungal infections in children.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelAntifungal pharmacotherapy for invasive mould infections.The lipid formulations of amphotericin B.How to treat fungal infections in ICU patients.Invasive aspergillosis in patients with hematologic malignancies.Management of infectious complications in the hematopoietic stem cell transplant recipient.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders.Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic/Oncologic DiseasesRecent advances in antifungal pharmacotherapy for invasive fungal infections.New developments in antifungal strategy.Liposomal amphotericin B: clinical experience and perspectives.Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.Amphotericin B-associated hyperbilirubinemia: case report and review of the literature.Fungal pneumonia due to molds in patients with hematological malignancies.Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature
P2860
Q24193811-69644775-83B9-44C7-B673-C575A7870F6BQ24239978-0B3524FE-898C-4EB6-A144-BE9BB70A8C2EQ26740363-88E43C1D-379E-41A4-A161-43794F871AFAQ27023320-8E9AA821-679E-433A-9D41-853366D8B638Q27025299-9901B564-BA4D-45BF-A2DC-960BB9C589F4Q30240770-F7C70DAF-BE1C-4EE8-8491-3ABD4A08BA72Q30355939-365F4290-4B4E-4E76-808C-2E708333B112Q30887348-9A105F90-461D-43B2-9652-3F44926F82E7Q31161843-8ACFBF0A-1D56-4876-A554-579339F0D2A6Q33371455-2A58381F-DE39-4BA7-9B66-1EEF5D77C59EQ33573788-0051E1F9-AE20-4C99-870C-64FEB568BFBCQ33613647-41E9622C-8B79-4D86-9475-199C50EB606DQ33622932-F9E825D4-D36E-40E3-B536-9DB7CE8D94B2Q33719294-B87F5A8C-BC0F-48D3-8645-61E953FC0A49Q33722067-F1FABDAB-F0C0-4C31-93E5-760CC019CB69Q33876645-714EC68B-1A83-46FF-8792-429980C76B73Q33896940-B027D45B-4D9C-44B5-B0CB-88D2F3B59475Q34230175-07AEF673-2CD5-4646-8C56-F9DAEC865E29Q34237335-01BF37E3-A8EB-4D0A-A4CC-F9FB92ABAE53Q34357504-58C59FEE-7593-4E51-8D9B-81530528FD4CQ34437094-776265C7-C538-4AD9-A861-9678ADA16631Q34532546-E00F87C1-C433-441A-9E4D-806D7D5D3AB1Q34546811-8F098FC3-A356-4EAE-84F2-002CCEBF386FQ34680675-B7743423-37CB-4737-9956-9539D302FABEQ35058091-299DA43D-6B91-4B13-AA80-5AF9FE450E07Q35183734-A9DEC2A2-FD7C-4034-9152-84AEFA97FD23Q35568846-46F33242-2244-4D31-9C71-0FBF7B5E6F50Q35616161-81022440-0CDF-477B-A7A6-5C3B299C3511Q35675979-08E001E6-7A94-4672-A4AE-2E1893194065Q35746695-2F8E59D4-E6EC-432E-A41A-408510664205Q35782575-13D9C24E-0960-4E1E-A2CF-D2E1BFDB3E7FQ35889014-B694DD69-7005-422E-A016-F5F81827C780Q35905124-66FA4C35-ED78-4FB6-91CE-1C83AACDBD41Q35917383-09B2B27D-4F94-4E64-ABA5-5D1A52300E24Q35917388-BCFBB13D-C8F3-4732-81A6-EFEE6394833CQ36140647-83F1B7CB-0667-4F88-8436-E6C637AABF73Q36326220-CEB16F6C-B415-42C3-961A-14E568D4CEE2Q36551571-9F6F636F-A46E-40D7-A862-CD9728609133Q36616182-0CF58639-33B8-4144-88DA-ECDCEE4560EEQ36688610-CF90383B-C188-4C00-A2B4-171C1313E33C
P2860
A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A double-blind, randomized, co ...... in immunocompromised patients.
@en
type
label
A double-blind, randomized, co ...... in immunocompromised patients.
@en
prefLabel
A double-blind, randomized, co ...... in immunocompromised patients.
@en
P2093
P2860
P356
P1476
A double-blind, randomized, co ...... in immunocompromised patients.
@en
P2093
Jo-Anne van Burik
John R Wingard
Larry Pietrelli
Marc Gurwith
Mary H White
Michel Laverdiere
Pranatharthi Chandrasekar
Raleigh Bowden
Sharon Safrin
P2860
P304
P356
10.1086/341401
P407
P577
2002-07-25T00:00:00Z